Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CHO PharmaROCO:6586 +7.69%25 3-Year RORE % is -6.08 as of Dec. 2025. GuruFocus rates ROCO:6586 with a GF Score™ of 25/100. The stock has 4 warning signs investors should review. Among 1,289 Biotechnology companies, CHO Pharma ranks better than 56.48% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
CHO Pharma's 3-Year RORE % for the quarter that ended in Dec. 2025 was -6.08%.
The industry rank for CHO Pharma's 3-Year RORE % or its related term are showing as below:
ROCO:6586's 3-Year RORE % is ranked better than 56.48% of 1289
companies
in the Biotechnology industry
Industry Median: -11.55
vs ROCO:6586: -6.08
CHO Pharma (ROCO:6586) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
CHO Pharma 3-Year RORE % Related Terms
CHO Pharma 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for CHO Pharma's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6586 vs VRTX, REGN, RVMD: 3-Year RORE % Comparison
For the Biotechnology subindustry, CHO Pharma's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CHO Pharma 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CHO Pharma's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where CHO Pharma's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
CHO Pharma (ROCO:6586) has a 3-Year RORE % of -6.08 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on CHO Pharma and its competitors. According to the industry distribution chart, CHO Pharma ranks #561 out of 1289 companies in the Biotechnology industry, placing it in the top 43.5%.
Is CHO Pharma's 3-Year RORE % too high?
CHO Pharma's current 3-Year RORE % is -6.08. Based on the distribution chart, CHO Pharma ranks #561 out of 1289 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CHO Pharma has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does CHO Pharma's 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CHO Pharma ranks #561 out of 1289 companies for 3-Year RORE %. This puts CHO Pharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on CHO Pharma and its competitors. CHO Pharma's current 3-Year RORE % is -6.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CHO Pharma stock overvalued right now?
CHO Pharma (ROCO:6586) has a current 3-Year RORE % of -6.08. The current 3-Year RORE % is -6.08. CHO Pharma's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For CHO Pharma (ROCO:6586), the current 3-Year RORE % is -6.08 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CHO Pharma Inc is a biopharmaceutical company mainly focused on the development and commercialization of innovative products based on the proprietary glycan engineering technologies. It offers antibodies, such as CHO-H01, CHO-H02, CHO-A04 for cancer; CHO-H03, an antibody for autoimmune disease; CHO-S05 dual-effect anti-flu drugs; and CHO-V06 glycan-based vaccines and drugs.
25GF Score
Get the complete analysis for ROCO:6586
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6586 has been successfully added to your 
